Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

60 Degrees Pharmaceuticals (SXTP) FCF Margin (2022 - 2025)

60 Degrees Pharmaceuticals (SXTP) has disclosed FCF Margin for 4 consecutive years, with 484.25% as the latest value for Q3 2025.

  • On a quarterly basis, FCF Margin rose 76859.0% to 484.25% in Q3 2025 year-over-year; TTM through Sep 2025 was 726.36%, a 13470.0% increase, with the full-year FY2024 number at 946.69%, up 86759.0% from a year prior.
  • FCF Margin was 484.25% for Q3 2025 at 60 Degrees Pharmaceuticals, up from 1483.62% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 262.42% in Q4 2022 to a low of 7305.38% in Q3 2023.
  • A 4-year average of 1328.32% and a median of 978.31% in 2025 define the central range for FCF Margin.
  • Peak YoY movement for FCF Margin: plummeted -712365bps in 2023, then skyrocketed 605255bps in 2024.
  • 60 Degrees Pharmaceuticals' FCF Margin stood at 262.42% in 2022, then crashed by -136bps to 95.06% in 2023, then plummeted by -613bps to 677.97% in 2024, then rose by 29bps to 484.25% in 2025.
  • Per Business Quant, the three most recent readings for SXTP's FCF Margin are 484.25% (Q3 2025), 1483.62% (Q2 2025), and 978.31% (Q1 2025).